These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30787211)

  • 1. The impact of Pompe disease on smooth muscle: a review.
    McCall AL; Salemi J; Bhanap P; Strickland LM; Elmallah MK
    J Smooth Muscle Res; 2018; 54(0):100-118. PubMed ID: 30787211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Airway smooth muscle dysfunction in Pompe (
    Keeler AM; Liu D; Zieger M; Xiong L; Salemi J; Bellvé K; Byrne BJ; Fuller DD; ZhuGe R; ElMallah MK
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L873-L881. PubMed ID: 28336814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen accumulation in smooth muscle of a Pompe disease mouse model.
    McCall AL; Dhindsa JS; Bailey AM; Pucci LA; Strickland LM; ElMallah MK
    J Smooth Muscle Res; 2021; 57(0):8-18. PubMed ID: 33883348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GAA deficiency disrupts distal airway cells in Pompe disease.
    El Haddad L; Lai E; Murthy PKL; Biswas DD; Soufny R; Roger AL; Tata PR; ElMallah MK
    Am J Physiol Lung Cell Mol Physiol; 2023 Sep; 325(3):L288-L298. PubMed ID: 37366541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycogenosome accumulation in the arrector pili muscle in Pompe disease.
    Katona I; Weis J; Hanisch F
    Orphanet J Rare Dis; 2014 Feb; 9():17. PubMed ID: 24495340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The respiratory neuromuscular system in Pompe disease.
    Fuller DD; ElMallah MK; Smith BK; Corti M; Lawson LA; Falk DJ; Byrne BJ
    Respir Physiol Neurobiol; 2013 Nov; 189(2):241-9. PubMed ID: 23797185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
    Schoser B; Hill V; Raben N
    Neurotherapeutics; 2008 Oct; 5(4):569-78. PubMed ID: 19019308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results.
    Hamdan MA; Almalik MH; Mirghani HM
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S431-6. PubMed ID: 19067231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand.
    Ngiwsara L; Wattanasirichaigoon D; Tim-Aroon T; Rojnueangnit K; Noojaroen S; Khongkraparn A; Sawangareetrakul P; Ketudat-Cairns JR; Charoenwattanasatien R; Champattanachai V; Kuptanon C; Pangkanon S; Svasti J
    BMC Med Genet; 2019 Sep; 20(1):156. PubMed ID: 31510962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of muscle pathology in infantile Pompe disease.
    Schänzer A; Kaiser AK; Mühlfeld C; Kulessa M; Paulus W; von Pein H; Rohrbach M; Viergutz L; Mengel E; Marquardt T; Neubauer B; Acker T; Hahn A
    Neuromuscul Disord; 2017 Feb; 27(2):141-152. PubMed ID: 27927596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What's new and what's next for gene therapy in Pompe disease?
    Roger AL; Sethi R; Huston ML; Scarrow E; Bao-Dai J; Lai E; Biswas DD; El Haddad L; Strickland LM; Kishnani PS; ElMallah MK
    Expert Opin Biol Ther; 2022 Sep; 22(9):1117-1135. PubMed ID: 35428407
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.